Praziquantel paediatric formulation - Pediatric Praziquantel Consortium

Drug Profile

Praziquantel paediatric formulation - Pediatric Praziquantel Consortium

Alternative Names: L-praziquantel; L-PZQ; L-PZQ ODT; MSC-1028703; MSC-1028703A; MSC-2499550A; PZQ ODT; Rac-PZQ ODT; Racemate PZQ ODT

Latest Information Update: 19 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pediatric Praziquantel Consortium
  • Class 3-ring heterocyclic compounds; Anthelmintics; Cyclohexanes; Isoquinolines; Pyrazines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Schistosomiasis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Jun 2016 Phase-II clinical trials in Schistosomiasis (In children, In infants) in Germany (PO) (NCT02806232)
  • 01 May 2015 Merck completes a phase-I trial in Schistosomiasis (In volunteers, In children) in Tanzania (PO) (NCT02315352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top